Can Females Get Gout? Yes — Why Postmenopause Raises the Risk After 60

Can females get gout? Yes. Women do develop gout, but their risk is roughly four to ten times lower than men's before menopause, then climbs sharply after it. The reason is estrogen: it keeps serum urate lower by increasing renal uric acid excretion. Once estrogen falls, urate levels rise, and gout risk converges toward male rates. In women, gout typically appears after age 60, often in the big toe or midfoot, and is more frequently misdiagnosed as osteoarthritis or a bunion. The postmenopausal rise is real and clinically underrecognized.

The Urate Mechanism: Why Estrogen Changes the Math

Gout is a crystal arthritis, not simply a "high uric acid" label. When serum urate exceeds the saturation threshold of about 6.8 mg/dL, monosodium urate crystals can form in joints and soft tissue. The immune system then attacks those crystals, producing the sudden heat, swelling, and severe pain of a flare. Everything about who gets gout flows from how high urate runs and for how long.

Sex hormones sit directly on that pathway. Estrogen increases renal clearance of uric acid, so premenopausal women typically run serum urate roughly 1 to 2 mg/dL lower than age-matched men. That relatively small gap matters enormously because the distribution of urate is continuous: shaving 1 to 2 mg/dL off the whole population pushes far fewer women across the 6.8 mg/dL crystal threshold.

In plain terms: estrogen works like a drainage valve for urate, and menopause partially closes that valve.

The mechanism is not purely hormonal. Body composition shifts after menopause, with visceral fat gain and rising insulin resistance. Hyperinsulinemia reduces renal urate excretion, adding a second push upward. Diuretic use for hypertension, which is common in older women, adds a third. So the postmenopausal rise in urate reflects at least three stacked drivers rather than estrogen alone.

How Common Is Gout in Women? The Numbers

Gout is genuinely male-predominant, which is exactly why female cases get missed. In high-income countries, the overall prevalence sits around 3 to 4 percent of adults, but the sex ratio is skewed. Before age 40, gout in women is uncommon enough that it should prompt a second look at the diagnosis. By the seventh and eighth decades, the female share of cases rises substantially.

The age of onset is the single most useful discriminator. Male gout peaks in the 40s and 50s. Female gout peaks a decade or more later, most often after 60. A first attack in a 72-year-old woman is entirely plausible. A first attack in a 35-year-old woman with regular cycles is a reason to check for something else, including genetic urate disorders or kidney disease.

Comorbidity patterns also diverge. Women with gout carry higher rates of hypertension, chronic kidney disease, and diuretic use at diagnosis than men do. They are more likely to have polyarticular involvement and to tophi at presentation. In other words, female gout tends to be diagnosed later and in a more advanced, complicated state.

A Timeline: From Estrogen Loss to First Flare

Gout in women is not a switch that flips at menopause. It is a slow accumulation, and the time course helps explain why the diagnosis lags.

The important takeaway: a woman can have asymptomatic hyperuricemia for a decade or more before her first attack. That silent window is where prevention and monitoring live.

Why Women's Gout Gets Missed: Symptoms and Edge Cases

Female gout looks different enough that it slips past both patients and clinicians. The classic big-toe attack is less dominant. Women more often present with midfoot, ankle, or knee involvement, and polyarticular disease at first presentation is more frequent. Because osteoarthritis is common in the same age group, an inflamed joint in a 65-year-old woman is easily attributed to wear and tear.

There is a specific trap worth naming. Postmenopausal women have higher rates of hallux valgus (bunions) and midfoot osteoarthritis. Both produce pain in the same territory where gout flares. A clinician who sees a painful first metatarsophalangeal joint in an older woman may anchor on the bunion and never check a urate level. The confirming test is joint aspiration with crystal identification, or at minimum a serum urate drawn well after the flare settles.

A second edge case is the woman with a normal serum urate during an acute attack. Urate can fall transiently during a flare, so a "normal" value drawn mid-attack does not exclude gout. Rechecking two to four weeks later is the correct move. This single caveat prevents a large share of missed diagnoses in women.

A third edge case is diuretic-associated gout. Thiazide and loop diuretics raise urate and are prescribed heavily to older women for hypertension and heart failure. When a woman on a thiazide develops a first-ever hot joint, diuretic-induced gout belongs high on the differential.

Hormone Therapy, Pregnancy, and Other Variations

Hormone therapy after menopause is one of the more interesting variables. Observational data suggest estrogen-containing hormone therapy is associated with somewhat lower serum urate, consistent with the clearance mechanism. The effect is modest and not a reason to prescribe hormone therapy, but it is a useful explanation when a woman on therapy has lower urate than expected. Conversely, stopping therapy can unmask a rise.

Pregnancy is a natural experiment in the other direction. Urate typically falls during pregnancy because of increased renal clearance and plasma volume expansion, so gout flares are rare in pregnancy. This reinforces the estrogen-clearance model. Gout appearing during pregnancy should raise suspicion for an underlying cause such as preeclampsia, which can alter urate handling.

Genetics cut across sex. Familial urate transporter variants can produce gout in younger women, and these cases are the exception that proves the age rule. A premenopausal woman with gout and a strong family history deserves genetic and renal evaluation rather than reassurance that "women don't get gout."

The Urate-Lowering Decision: Thresholds and Targets

The treatment logic is identical in women and men, but the thresholds get muddled in practice. Here is the reconciliation. Diagnosis rests on crystals or a compatible clinical picture; the 6.8 mg/dL saturation threshold explains crystal formation; treatment initiation is generally considered above 9 mg/dL in asymptomatic patients or after a second flare; and the therapeutic target for someone on urate-lowering therapy is below 6 mg/dL, or below 5 mg/dL for severe, tophaceous disease. These are different numbers serving different purposes, not competing definitions.

Per the 2020 American College of Rheumatology gout management guideline, urate-lowering therapy is strongly recommended for patients with tophi, frequent flares, or advanced disease, and the treat-to-target approach aims for sustained urate below 6 mg/dL. Women are frequently undertreated relative to these targets. One recurring problem is that female patients are started on urate-lowering therapy at lower flare counts and then not titrated, leaving them above target for years.

Allopurinol remains first-line. The old advice to avoid it in women with reduced kidney function has been largely corrected: starting at a low dose and titrating upward is appropriate even in chronic kidney disease. Febuxostat is an alternative. The non-obvious professional caveat is dose titration: many women are maintained on 100 mg of allopurinol indefinitely when 200 to 300 mg is what it takes to reach below 6 mg/dL. Underdosing is the quiet epidemic.

Red-flag features that warrant urgent evaluation rather than routine management:

• A first gout-like attack in a joint that is also red, hot, and systemically unwell, which can mimic septic arthritis
• Fever with a hot joint at any age
• Rapidly progressive polyarticular attacks in a woman on diuretics or with kidney disease
• New tophi or kidney stones alongside a first flare
• Gout in a premenopausal woman, prompting evaluation for genetic or renal causes

What to Actually Do: Practical Steps for Women

Practical management starts with knowing the number. Any woman over 60 with a hot, swollen joint should have a serum urate checked, ideally two to four weeks after the flare. A value persistently above 6.8 mg/dL supports the diagnosis and opens the prevention conversation. If the value is normal, still consider crystal confirmation rather than dismissing gout.

Review medications with a clinician. Thiazide and loop diuretics, low-dose aspirin, and some immunosuppressants raise urate. Substituting an alternative antihypertensive, where clinically appropriate, can lower urate meaningfully. This is a discussion with a prescriber, not a self-directed change.

Address the modifiable drivers. Weight reduction, limiting alcohol (especially beer), and reducing fructose-sweetened drinks all lower urate. Hydration helps. These are modest levers individually but additive over years. For women with recurrent flares or tophi, urate-lowering therapy with titration to below 6 mg/dL is the definitive intervention, and it works just as well in women as in men when dosed adequately.

Limitations: What the Evidence Does Not Settle

Honest gaps remain. Much of the sex-specific gout literature is observational, so the estrogen-clearance mechanism is well supported but not proven in randomized trials. The precise magnitude of the postmenopausal risk rise varies across populations, and most large cohorts are drawn from high-income countries where diuretic use and obesity patterns differ from elsewhere. The female-specific flare phenotype is described but lacks a validated clinical prediction tool.

Perhaps the largest limitation is diagnostic behavior rather than biology. Because gout is framed as a male disease, women are less likely to be tested and more likely to be labeled with osteoarthritis. That underdiagnosis means published incidence figures may understate female gout. The practical implication is straightforward: the sex ratio is real, but the diagnostic reflex should not be. Any older woman with a hot joint and an elevated urate deserves to have gout taken seriously.